Journal
RADIOTHERAPY AND ONCOLOGY
Volume 120, Issue 3, Pages 486-492Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.radonc.2016.05.019
Keywords
Radiation; Brachytherapy; CT; MRI; Vaginal cancer
Funding
- NIH [R21 167800]
- Boerner Family Fund
- St. Laurent Family Fund
- Chua Family Fund
- [P41EB 015898]
Ask authors/readers for more resources
Purpose: To compare clinical outcomes of image-based versus non-image-based interstitial brachytherapy (IBBT) for vaginal cancer. Methods and materials: Of 72 patients with vaginal cancer treated with brachytherapy (BT), 47 had image guidance (CT = 31, MRI = 16) and 25 did not. Kaplan-Meier (KM) estimates were generated for any recurrence, local control (LC), disease-free interval (DFI), and overall survival (OS) and Cox models were used to assess prognostic factors. Results: Median age was 66 and median follow-up time was 24 months. Median cumulative EQD2 dose was 80.8 Gy in the non-IBBT group and 77 Gy in the IBBT group. For non-IBBT versus IBBT, the 2-year KM LC was 71% vs. 93% (p = 0.03); DFI was 54% vs. 86% (p = 0.04); and OS 52% vs. 82% (p = 035). On multivariate analysis, IBBT was associated with better DFI (HR 0.24, 95% CI 0.07-0.73). Having any 2 or more of chemotherapy, high-dose-rate (HDR) BT or IBBT (temporally correlated variables) significantly reduced risk of relapse (HR = 0.33, 95% CI = 0.13-0.83), compared to having none of these factors. Conclusion: Over time, the use of chemotherapy, HDR, and IBBT has increased in vaginal cancer. The combination of these factors resulted in the highest rates of disease control. Image-guided brachytherapy for vaginal cancer patients maximizes disease control. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available